CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus
More Jobs, Cost Cuts Bring Year’s Total To $1bn
The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.
You may also be interested in...
Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023
Christopher Viehbacher told his first earnings call as CEO that a review is under way to reverse Biogen’s fortunes, but noted Leqembi will not be a meaningful contributor while treatment and reimbursement bottlenecks remain.
Biogen Lures Viehbacher Back From Venture Capital As CEO
Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.
Biogen Weighs Aduhelm Lessons Ahead Of Lecanemab Launch
Plans for launching a second Alzheimer's drug, lecanemab, will be scaled back compared to Aduhelm, the firm predicted, though partner Eisai has not finalized Biogen's commercial role yet.